Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Department of Pediatrics, Women & Infants Hospital of Rhode Island; The Alpert Medical School of Brown University, Barrington, RI 02806, USA.
Clin Perinatol. 2024 Sep;51(3):617-628. doi: 10.1016/j.clp.2024.04.004. Epub 2024 May 22.
This article summarizes the current evidence regarding inflammatory biomarkers (placental and postnatal) and provides a comprehensive understanding of their roles: (1) diagnostic accuracy to predict the severity of hypoxic-ischemia encephalopathy (HIE), (2) value in assessing treatment responses, and (3) prediction of both short- and long-term neurodevelopmental outcomes. In the early critical stages of perinatal asphyxia, inflammatory biomarkers may guide clinical decision-making. Additional research is required to increase our understanding of the optimal utility of biomarkers to predict the severity, evolution, and developmental outcomes after exposure to HIE.
本文总结了目前关于炎症生物标志物（胎盘和产后）的证据，并提供了对其作用的全面理解：（1）预测缺氧缺血性脑病（HIE）严重程度的诊断准确性，（2）评估治疗反应的价值，以及（3）预测短期和长期神经发育结果。在围产期窒息的早期关键阶段，炎症生物标志物可能有助于指导临床决策。需要进一步研究以增加我们对生物标志物最佳用途的理解，以预测 HIE 暴露后的严重程度、演变和发育结果。
